Merck MRK

Merck has invested $250 million in collaboration with Moderna to develop a personalized cancer vaccine, mRNA-4157/V940, building on their partnership initiated in 2016. This strategic move is part of Merck's efforts to enhance its oncology portfolio amid the looming patent expiration of its leading drug, Keytruda, which currently represents over half of its revenue. Despite a strong financial performance with positive quarterly results and an adjusted annual revenue outlook, Merck faces significant challenges as it restructures operations in anticipation of potential financial decline post-Keytruda. The company aims to attract investment interest while navigating a competitive pharmaceutical landscape.